UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Diagnosis of latent tuberculosis infection (tuberculosis screening) in HIV-uninfected adults

Authors
Madhukar Pai, MD, PhD
Dick Menzies, MD, MSc
Section Editor
C Fordham von Reyn, MD
Deputy Editor
Elinor L Baron, MD, DTMH

INTRODUCTION

Treatment of individuals with active tuberculosis (TB) is the first priority for tuberculosis control; an important second priority is identification and treatment of individuals with latent tuberculosis infection (LTBI) [1].

In most individuals, Mycobacterium tuberculosis infection is contained initially by host defenses, and infection remains latent. However, latent infection has the potential to develop into active disease at any time. Identification and treatment of latent tuberculosis infection can reduce the risk of development of disease by as much as 90 percent [2] and so has potential to protect the health of the individuals as well as the public by reducing the number of potential sources of infection [3,4].

There are two major tests for identification of latent tuberculosis infection: the tuberculin skin test (TST) and the interferon gamma release assay (IGRA) [5,6]. Both tests evaluate cell-mediated immunity.

Use of TST for diagnosis of LTBI in HIV-uninfected patients will be reviewed here. Management of LTBI for patients with HIV or receiving tumor necrosis factor-alpha inhibitors is discussed in detail separately, as are issues related to TB screening in children and treatment of latent tuberculosis infection in HIV-uninfected patients. (See "Treatment of latent tuberculosis infection in HIV-infected adults" and "Latent tuberculosis infection in children" and "Tumor necrosis factor-alpha inhibitors and mycobacterial infections" and "Interferon-gamma release assays for diagnosis of latent tuberculosis infection".)

INDICATIONS FOR TESTING

The goal of testing for latent tuberculosis infection (LTBI) is to identify individuals who are at increased risk for the development of tuberculosis (TB) and therefore would benefit from treatment of LTBI [7,8]. Only those who would benefit from treatment should be tested, so a decision to test presupposes a decision to treat if the test is positive.

                       

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Thu Oct 27 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. World Health Organization. Guidelines on the management of latent tuberculosis infection. WHO, Geneva 2015. http://www.who.int/tb/publications/ltbi_document_page/en/ (Accessed on March 02, 2016).
  2. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999; 3:847.
  3. Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004; 350:2060.
  4. Rieder HL. Interventions for Tuberculosis Control and Elimination. International Union Against Tuberculosis and Lung Disease, 2002.
  5. Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med 2015; 372:2127.
  6. Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J 2015; 46:1563.
  7. Horsburgh CR Jr, Rubin EJ. Clinical practice. Latent tuberculosis infection in the United States. N Engl J Med 2011; 364:1441.
  8. Mancuso JD, Tribble D, Mazurek GH, et al. Impact of targeted testing for latent tuberculosis infection using commercially available diagnostics. Clin Infect Dis 2011; 53:234.
  9. Kahwati LC, Feltner C, Halpern M, et al. Screening for Latent Tuberculosis Infection in Adults: An Evidence Review for the U.S. Preventive Services Task Force, Agency for Healthcare Research and Quality, Rockville, MD 2016.
  10. Kahwati LC, Feltner C, Halpern M, et al. Primary Care Screening and Treatment for Latent Tuberculosis Infection in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2016; 316:970.
  11. Schwartzman K, Menzies D. Tuberculosis screening of immigrants to low-prevalence countries. A cost-effectiveness analysis. Am J Respir Crit Care Med 2000; 161:780.
  12. Schwartzman K, Oxlade O, Barr RG, et al. Domestic returns from investment in the control of tuberculosis in other countries. N Engl J Med 2005; 353:1008.
  13. Campbell JR, Chen W, Johnston J, et al. Latent tuberculosis infection screening in immigrants to low-incidence countries: a meta-analysis. Mol Diagn Ther 2015; 19:107.
  14. Marais BJ, Gie RP, Schaaf HS, et al. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis 2004; 8:392.
  15. Comstock GW, Edwards LB, Livesay VT. Tuberculosis morbidity in the U.S. Navy: its distribution and decline. Am Rev Respir Dis 1974; 110:572.
  16. Stead WW, To T, Harrison RW, Abraham JH 3rd. Benefit-risk considerations in preventive treatment for tuberculosis in elderly persons. Ann Intern Med 1987; 107:843.
  17. Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978; 117:991.
  18. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000; 161:S221.
  19. The Online TST/QFT Interpreter. Version 2.0. http://www.tstin3d.com/index.html (Accessed on September 24, 2010).
  20. Pai M, Kunimoto D, Jamieson F, Menzies D. Diagnosis of Latent TB Infection. In: Canadian Tuberculosis Standards, 7th ed, Menzies D. (Ed), Canadian Lung Association and Public Health Agency of Canada, Ottawa 2013.
  21. Hoppe LE, Kettle R, Eisenhut M, et al. Tuberculosis--diagnosis, management, prevention, and control: summary of updated NICE guidance. BMJ 2016; 352:h6747.
  22. COMSTOCK GW, EDWARDS LB, PHILIP RN, WINN WA. A COMPARISON IN THE UNITED STATES OF AMERICA OF TWO TUBERCULINS, PPD-S AND RT 23. Bull World Health Organ 1964; 31:161.
  23. Menzies D, Doherty TM. Diagnosis of latent tuberculosis infection. In: Reichman and Hershfield's Tuberculosis, a comprehensive international approach, Raviglione MC (Ed), Informa Healthcare USA, New York 2006. p.215.
  24. DUBOCZY BO, BROWN BT. Multiple readings and determination of maximal intensity of tuberculin reaction. Am Rev Respir Dis 1961; 84:60.
  25. Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 1999; 159:15.
  26. Jensen PA, Lambert LA, Iademarco MF, et al. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep 2005; 54:1.
  27. World Health Organization. Guidelines for the prevention of tuberculosis in health care facilities in resource-limited settings. WHO/CDS/TB/99.269. IJTLD 1999.
  28. Menzies R, Vissandjee B, Rocher I, St Germain Y. The booster effect in two-step tuberculin testing among young adults in Montreal. Ann Intern Med 1994; 120:190.
  29. Richards NM, Nelson KE, Batt MD, et al. Tuberculin test conversion during repeated skin testing, associated with sensitivity to nontuberculous mycobacteria. Am Rev Respir Dis 1979; 120:59.
  30. Gordin FM, Perez-Stable EJ, Flaherty D, et al. Evaluation of a third sequential tuberculin skin test in a chronic care population. Am Rev Respir Dis 1988; 137:153.
  31. FURTHER studies of geographic variation in naturally acquired tuberculin sensitivity. Bull World Health Organ 1955; 12:63.
  32. Centers for Disease Control and Prevention. Guide to Vaccine Contraindications and Precautions. Department of Health and Human Services. Available at: http://www.cdc.gov/vaccines/recs/vac-admin/downloads/contraindications-guide-508.pdf
  33. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 2006; 10:1192.
  34. A World Atlas of BCG Vaccination Policies and Practices http://www.bcgatlas.org/ (Accessed on April 01, 2009).
  35. Vinkeles Melchers NV, van Elsland SL, Lange JM, et al. State of affairs of tuberculosis in prison facilities: a systematic review of screening practices and recommendations for best TB control. PLoS One 2013; 8:e53644.
  36. Arshad S, Bavan L, Gajari K, et al. Active screening at entry for tuberculosis among new immigrants: a systematic review and meta-analysis. Eur Respir J 2010; 35:1336.
  37. Rieder H. What is the role of case detection by periodic mass radiographic examination in tuberculosis control?. In: Toman’s Tuberculosis: Case detection, treatment, and monitoring – questions and answers, 2nd ed, Frieden, T. (Eds), World Health Organization, Geneva 2004. p.72.
  38. Tarlo SM, Day JH, Mann P, Day MP. Immediate hypersensitivity to tuberculin. In vivo and in vitro studies. Chest 1977; 71:33.
  39. Youssef E, Wooltorton E. Serious allergic reactions following tuberculin skin tests. CMAJ 2005; 173:34.
  40. Froeschle JE, Ruben FL, Bloh AM. Immediate hypersensitivity reactions after use of tuberculin skin testing. Clin Infect Dis 2002; 34:E12.
  41. Richard Menzies, MD, MSc, personal communication.
  42. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. Adv Tuberc Res 1969; 17:28.